Highlights from Implantica AG's Annual General Meeting
On a recent date, the annual general meeting (AGM) of Implantica AG (publ) took place in Ruggell. This important gathering allowed shareholders to review key proposals and resolutions put forth by the board of directors, all of which were adopted. Below is a detailed overview of the notable decisions made during this meeting.
Annual Report Adoption
The AGM successfully adopted the annual report for the financial year 2024, which included the statutory and consolidated financial statements of the company. The reported figures received acknowledgment from the auditors, confirming the accuracy and completeness of the financial disclosures.
Financial Resolutions and Board Discharge
One significant resolution was to carry forward the net loss reported for 2024, indicating a strategic decision to focus on future growth rather than immediate dividend distributions to shareholders. Additionally, the meeting discharged the members of the board of directors, executive management, and auditors from liability for their contributions during the past financial year.
Remuneration Structure
During the AGM, attendees approved the total remuneration for the board of directors, set at TEUR 106, and for executive management, amounting to TEUR 821. This remuneration encompasses all forms of compensation, including fixed salaries, pension contributions, and long-term share-based incentives that align management's interests with the company’s ongoing success.
Board Members and Committees
Moreover, the meeting saw the re-election of several key figures in the board. Liselott Kilaas was reinstated as chairman while Johan Bojs was re-elected as vice-chairman for another term. Additionally, members engaging with the nomination and remuneration committee were reviewed, ensuring the board's continuity and stability.
Independent Proxy and Auditor Re-Election
The AGM also re-elected Philipp Wanger, a legal advisor based in Vaduz, as the independent proxy until the next shareholders' meeting. Furthermore, KPMG was confirmed for another year as the company's auditor, underscoring trust in their ability to uphold financial integrity for 2025.
Amendments to Articles of Association
Significant amendments were made to the Articles of Association, particularly Article 4a para. 1, granting the Board of Directors the power to resolve on new share issues, with or without deviations from shareholders' preferential rights. This flexibility allows the company to respond effectively to market conditions and opportunities.
Innovations in Medtech by Implantica
Implantica is at the forefront of medical technology innovations, focusing on solutions that enhance the quality of life for patients. One of their flagship products is RefluxStop™, which aims to change the landscape of anti-reflux treatment significantly. With the support of successful clinical trials, this implantable device is poised to be a game-changer in gastroesophageal reflux management.
The company is also actively developing an eHealth platform that monitors health parameters and facilitates remote treatment controls. This innovative approach not only enhances patient care but also enables seamless communication between patients and healthcare providers.
Company Contact and Information
For more inquiries regarding the AGM or any company updates, please reach out to Nicole Pehrsson, Chief Corporate Affairs Officer. Unfortunately, specific contact emails are not provided here, but her telephone number is widely available for further discussions.
Implantica is proudly listed on the Nasdaq First North Premier Growth Market, showcasing their ongoing commitment to growth and innovation in the medical technology sector.
Frequently Asked Questions
What key resolutions were made during the AGM?
The AGM adopted the annual report, approved financial resolutions including net loss carry-forward, and re-elected the board members and auditors.
Who were re-elected to the board during the meeting?
Liselott Kilaas as chairman, Johan Bojs as vice-chairman, alongside other directors like Tomas Puusepp and Stephan Siegenthaler.
What is the significance of the RefluxStop™ product?
RefluxStop™ is a CE-marked implant intended to significantly improve anti-reflux treatment options based on clinical trial success.
How does Implantica plan to innovate in healthcare?
Implantica aims to enhance patient monitoring and treatment through its eHealth platform, focusing on remote control and health management technologies.
Who can I contact for more information about Implantica?
For additional information, you can contact their Chief Corporate Affairs Officer, Nicole Pehrsson, using the company's listed telephone number.
